Seoul, South Korea

Chong Kun Dang Pharmaceutical Corporation


USPTO Granted Patents = 49



Trademarks = 2

Forward Citations = 111

Loading Chart...
Loading Chart...

208 inventors (with patents filed for the assignee):

goldMedal Yuntae Kim (7 out of 52 patents)

silverMedal Hyeseung Song (7 out of 7 patents)

bronzeMedal Jong Lae Lim (7 out of 8 patents)

4 Jung Taek Oh (6 out of 6 patents)

5 Min Hyo Ki (5 out of 7 patents)

6 Dohoon Kim (5 out of 30 patents)

7 Jaekwang Lee (5 out of 5 patents)

8 Daekwon Bae (5 out of 5 patents)

9 ChangSik Lee (5 out of 5 patents)

10 Chang Sik Lee (5 out of 19 patents)

11 Shin Jung Park (4 out of 4 patents)

12 Younghue Han (4 out of 4 patents)

13 Jaeki Min (4 out of 9 patents)

14 Miseon Bae (4 out of 4 patents)

15 Nina Ha (4 out of 4 patents)


Core Competencies:
Histone Deacetylase Inhibitors
Oxadiazole Derivatives
Pharmaceutical Composition
Gene Delivery
Cancer Treatment
Gastritis Treatment
Long-Acting Injectable
Transgenic Models
CETP Inhibitors
GPR119 Agonists
Naltrexone Microparticles
Erythropoietin Analogs

49 patents:

Chong Kun Dang Pharmaceutical Corporation is a leading pharmaceutical company based in South Korea. With a strong emphasis on research and development, Chong Kun Dang is dedicated to improving the health and well-being of people worldwide. The company specializes in developing innovative and high-quality pharmaceutical products across various therapeutic areas including cardiovascular, gastrointestinal, and central nervous system disorders. Chong Kun Dang's commitment to excellence has earned them a reputation as a trusted and reliable partner in the global healthcare industry.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

49 Patents

#98 in Seoul

#313 in South Korea

#13,874 in the World

...
Seoul, South Korea
Forward Citations = 111

208 inventors:

Please report any incorrect information to support@idiyas.com
Loading…